Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann C Collier

Showing results (171-180 of 184) with videos related to

Pageof 19
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2014
Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER studyRobert K Heaton, Donald R Franklin, Reena Deutsch, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
Journal of Neurovirology|December 22, 2010
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsRobert K Heaton, Donald R Franklin, Ronald J Ellis, et al.
The Lancet. HIV|August 3, 2019
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn, Michael D Hughes, Justin Ritz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009David B Hanna, Kate Buchacz, Kelly A Gebo, et al.
Journal of the International AIDS Society|August 30, 2022
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon, Michael D Hughes, Robert Salata, et al.
Cell Reports. Medicine|October 5, 2020
Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV InfectionSean M Hughes, Claire N Levy, Fernanda L Calienes, et al.
AIDS (London, England)|December 5, 2023
The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapyJeffrey M Jacobson, Barbara K Felber, Huichao Chen, et al.
AIDS Research and Therapy|December 17, 2010
CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?Keri N Althoff, Kelly A Gebo, Stephen J Gange, et al.
The Journal of Infectious Diseases|August 8, 2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical StudiesGolnaz Namazi, Jesse M Fajnzylber, Evgenia Aga, et al.
Pageof 19

Showing results (171-180 of 184) with videos related to

Sort By:
Pageof 19
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2014
Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER studyRobert K Heaton, Donald R Franklin, Reena Deutsch, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
Journal of Neurovirology|December 22, 2010
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsRobert K Heaton, Donald R Franklin, Ronald J Ellis, et al.
The Lancet. HIV|August 3, 2019
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn, Michael D Hughes, Justin Ritz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009David B Hanna, Kate Buchacz, Kelly A Gebo, et al.
Journal of the International AIDS Society|August 30, 2022
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon, Michael D Hughes, Robert Salata, et al.
Cell Reports. Medicine|October 5, 2020
Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV InfectionSean M Hughes, Claire N Levy, Fernanda L Calienes, et al.
AIDS (London, England)|December 5, 2023
The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapyJeffrey M Jacobson, Barbara K Felber, Huichao Chen, et al.
AIDS Research and Therapy|December 17, 2010
CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?Keri N Althoff, Kelly A Gebo, Stephen J Gange, et al.
The Journal of Infectious Diseases|August 8, 2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical StudiesGolnaz Namazi, Jesse M Fajnzylber, Evgenia Aga, et al.
Pageof 19